| 摘要 |
This invention provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of benign prostate hyperplasia in a male subject, by administering to the subject a selective androgen receptor modulator (SARM) and/or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof as described herein. Besides, the invention provides a method of blocking the ability of dihydrotestosterone (DHT) to induce hyperplasia, a method of inhibiting the mitogenic action of Testosterone and DHT, a method of inhibiting recruitment of co-activators or co-regulators of androgen-responsive DNA comprising the step of contacting the androgen receptor with any one of a SARM compound and/or its isomer, the pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof as described herein. This invention also provides a method of inhibiting a 5α-reductase type 1 and/or type 2 enzyme, comprising contacting the enzyme with an effective 5α-reductase inhibitory amount of a selective androgen receptor modulator (SARM) and/or its isomer, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, as described herein. |
